Basics to advances in nanotherapy of colorectal cancer.

Antineoplastic Agents, Immunological / chemistry Clinical Trials as Topic Colorectal Neoplasms / drug therapy Drug Carriers Drug Compounding Gene Expression Regulation, Neoplastic / drug effects Gene Regulatory Networks / genetics Humans Immunotherapy Nanostructures
Colorectal cancer Drug delivery Immunotherapy Molecular pathogenesis Nanocarriers

Journal

Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 9 11 2019
medline: 20 11 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

Colorectal cancer (CRC) is the third most common cancer existing across the globe. It begins with the formation of polyps leading to the development of metastasis, especially in advanced stage patients, who necessitate intensive chemotherapy that usually results in a poor response and high morbidity owing to multidrug resistance and severe untoward effects to the non-cancerous cells. Advancements in the targeted drug delivery permit the targeting of tumor cells without affecting the non-tumor cells. Various nanocarriers such as liposomes, polymeric nanoparticles, carbon nanotubes, micelles, and nanogels, etc. are being developed and explored for effective delivery of cytotoxic drugs to the target site thereby enhancing the drug distribution and bioavailability, simultaneously subduing the side effects. Moreover, immunotherapy for CRC is being explored for last few decades. Few clinical trials have even potentially benefited patients suffering from CRC, still immunotherapy persists merely an experimental alternative. Assessment of the ongoing and completed trials is to be warranted for effective treatment of CRC. Scientists are paying efforts to develop novel carrier systems that may enhance the targeting potential of low therapeutic index chemo- and immune-therapeutics. Several preclinical studies have revealed the superior efficacy of nanotherapy in CRC as compared to conventional approaches. Clinical trials are being recruited to ascertain the safety and efficacy of CRC therapies. The present review discourses in a nutshell the molecular interventions including the genetics, signaling pathways involved in CRC, and advances in various strategies explored for the treatment of CRC with a special emphasis on nanocarriers based drug targeting.

Identifiants

DOI: 10.1007/s13346-019-00680-9 PMID: 31701486
pubmed: 31701486
doi: 10.1007/s13346-019-00680-9
pii: 10.1007/s13346-019-00680-9
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Drug Carriers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-338

Références

Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S23-6
pubmed: 19343144
Curr Mol Med. 2017;17(5):321-340
pubmed: 29210648
J Pharm Sci. 2018 Feb;107(2):690-697
pubmed: 29031952
Nat Commun. 2018 Jun 8;9(1):2237
pubmed: 29884866
Carbohydr Polym. 2013 Oct 15;98(1):711-20
pubmed: 23987403
Int J Biol Macromol. 2015 Feb;73:222-35
pubmed: 25478964
Curr Pharm Des. 2006;12(36):4669-84
pubmed: 17168771
Drug Dev Ind Pharm. 2016 Jan;42(1):136-149
pubmed: 26006330
Cell Tissue Res. 2017 Oct;370(1):29-39
pubmed: 28560691
Eur J Pharm Sci. 2018 Mar 1;114:166-174
pubmed: 29247686
Nat Rev Immunol. 2015 Oct;15(10):615-29
pubmed: 26358393
Drug Discov Ther. 2015 Oct;9(5):342-51
pubmed: 26632543
J Control Release. 2000 Mar 1;65(1-2):19-29
pubmed: 10699266
Gastrointest Cancer Res. 2012 Jan;5(1):19-27
pubmed: 22574233
JCI Insight. 2017 Apr 20;2(8):
pubmed: 28422758
PLoS One. 2014 Jun 25;9(6):e100732
pubmed: 24964012
World J Gastroenterol. 2016 Jan 14;22(2):582-99
pubmed: 26811609
Annu Rev Med. 2000;51:289-98
pubmed: 10774465
Drug Deliv. 2015 Feb;22(2):191-8
pubmed: 24437926
Int J Mol Sci. 2018 Jun 06;19(6):
pubmed: 29882764
Jpn J Clin Oncol. 2008 Dec;38(12):793-802
pubmed: 18988667
Clin Cancer Res. 2017 Jan 15;23(2):399-406
pubmed: 27435399
Curr Mol Med. 2015;15(7):621-33
pubmed: 26321756
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Carbohydr Polym. 2017 Feb 20;158:51-57
pubmed: 28024542
Int J Pharm. 2013 Jun 25;450(1-2):235-40
pubmed: 23624084
Acta Haematol. 1999;101(2):82-8
pubmed: 10202238
J Control Release. 2008 Dec 18;132(3):164-70
pubmed: 18571265
Mediators Inflamm. 2017;2017:5958429
pubmed: 28676732
Int J Nanomedicine. 2015 Mar 16;10:2051-63
pubmed: 25844036
Nanomaterials (Basel). 2018 Mar 27;8(4):
pubmed: 29584656
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40
pubmed: 9096394
World J Gastroenterol. 2007 Jun 7;13(21):2952-5
pubmed: 17589945
Anticancer Res. 2014 Feb;34(2):575-84
pubmed: 24510986
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Mol Pharm. 2014 Dec 1;11(12):4339-49
pubmed: 25350222
Carbohydr Res. 2011 May 1;346(6):801-6
pubmed: 21397214
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
Nanomedicine. 2013 Jul;9(5):675-85
pubmed: 23219878
Environ Mol Mutagen. 2004;44(1):44-55
pubmed: 15199546
Biomed Pharmacother. 2011 Feb;65(1):2-8
pubmed: 21177069
Colloids Surf B Biointerfaces. 2017 Jun 1;154:104-114
pubmed: 28329728
Nat Rev Immunol. 2012 Mar 22;12(4):269-81
pubmed: 22437939
Bioconjug Chem. 2000 Sep-Oct;11(5):664-73
pubmed: 10995209
Cancer Causes Control. 2002 May;13(4):383-93
pubmed: 12074508
Int J Nanomedicine. 2012;7:151-62
pubmed: 22275831
Acta Biomater. 2017 Jan 15;48:238-246
pubmed: 27815166
Eur J Gastroenterol Hepatol. 2017 Feb;29(2):144-152
pubmed: 27926660
Expert Opin Drug Deliv. 2012 Feb;9(2):141-9
pubmed: 22236045
J Biomed Mater Res A. 2018 Feb;106(2):349-359
pubmed: 28940736
Oncoimmunology. 2018 Mar 15;7(6):e1433981
pubmed: 29872568
Macromol Biosci. 2012 Aug;12(8):1060-7
pubmed: 22707328
Arch Pharm Res. 2015 Jan;38(1):42-51
pubmed: 24668152
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Pathology. 2018 Jan;50(1):49-59
pubmed: 29169633
Clin Oncol (R Coll Radiol). 2007 Dec;19(10):769-76
pubmed: 17950585
Biomaterials. 2016 Apr;86:92-105
pubmed: 26896610
Drug Deliv. 2014 Mar;21(2):101-9
pubmed: 24044613
Nano Lett. 2015 Feb 11;15(2):891-5
pubmed: 25584433
Eur J Pharm Sci. 2011 Apr 18;42(5):445-51
pubmed: 21182939
J Control Release. 2010 Dec 1;148(2):135-46
pubmed: 20797419
J Control Release. 2014 Sep 10;189:1-10
pubmed: 24956488
Cardiovasc Intervent Radiol. 2015 Apr;38(2):261-9
pubmed: 25537310
Int J Mol Sci. 2014 Apr 08;15(4):5852-73
pubmed: 24717409
Int J Nanomedicine. 2017 Sep 08;12:6677-6685
pubmed: 28932113
Int J Nanomedicine. 2017 Aug 08;12:5701-5715
pubmed: 28848348
Clin Lab Med. 2005 Mar;25(1):135-77
pubmed: 15749236
Recent Pat Drug Deliv Formul. 2014;8(2):111-25
pubmed: 24597612
BMJ. 1992 Apr 25;304(6834):1106-8
pubmed: 1586826
Drug Deliv. 2016 Jun;23(5):1773-87
pubmed: 26377238
J Microencapsul. 2017 Sep;34(6):513-521
pubmed: 28705043
J Gastrointestin Liver Dis. 2008 Mar;17(1):59-67
pubmed: 18392246
Int J Pharm. 2010 Nov 15;400(1-2):201-10
pubmed: 20804835
Curr Drug Targets. 2018;19(13):1498-1518
pubmed: 29384060
Ther Deliv. 2017 Jan;8(1):29-47
pubmed: 27982736
Hum Pathol. 2008 Apr;39(4):498-505
pubmed: 18342661
Crit Rev Ther Drug Carrier Syst. 2013;30(6):535-63
pubmed: 24099399
Mol Pharm. 2009 Jul-Aug;6(4):1092-9
pubmed: 19545174
Int J Nanomedicine. 2017 Mar 10;12:1941-1958
pubmed: 28331317
Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6
pubmed: 8629105
Cancer Res Treat. 2009 Mar;41(1):1-11
pubmed: 19688065
Acta Pharmacol Sin. 2017 Jun;38(6):885-896
pubmed: 28479604
Eur J Pharm Biopharm. 2012 Sep;82(1):58-65
pubmed: 22634237
J Control Release. 2016 May 10;229:10-22
pubmed: 26968799
World J Radiol. 2012 Sep 28;4(9):405-12
pubmed: 23024842
Biomacromolecules. 2017 Mar 13;18(3):1010-1018
pubmed: 28192653
J Biomater Appl. 2013 Mar;27(7):811-27
pubmed: 22274881
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
J Drug Deliv. 2014;2014:670815
pubmed: 24872894
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Int J Pharm. 2014 May 15;466(1-2):147-55
pubmed: 24614580
Crit Rev Oncol Hematol. 2013 Jun;86(3):232-50
pubmed: 23098684
Am J Pathol. 2013 May;182(5):1821-31
pubmed: 23499465
Int J Nanomedicine. 2014 Jun 19;9:3005-12
pubmed: 24971011
Adv Drug Deliv Rev. 2004 Mar 3;56(4):491-509
pubmed: 14969755
Biomacromolecules. 2018 Mar 12;19(3):803-815
pubmed: 29451980
Artif Cells Nanomed Biotechnol. 2018 Sep;46(6):1236-1247
pubmed: 28849671
Int J Biol Macromol. 2014 Aug;69:100-7
pubmed: 24854212
Biomaterials. 2017 Apr;124:195-210
pubmed: 28199887
Eur J Pharm Biopharm. 2008 Mar;68(3):618-25
pubmed: 17949957
ACS Appl Mater Interfaces. 2017 Mar 22;9(11):9470-9483
pubmed: 28252278
Nanomedicine (Lond). 2008 Apr;3(2):175-82
pubmed: 18373424
Int J Pharm. 2017 Jun 30;526(1-2):339-352
pubmed: 28455135
J Vasc Interv Radiol. 2009 Sep;20(9):1121-30; quiz 1131
pubmed: 19640737
Semin Cancer Biol. 1998 Aug;8(4):285-98
pubmed: 9870035
Curr Drug Targets. 2018 Feb 8;19(3):259-270
pubmed: 26853324
Crit Rev Oncol Hematol. 2010 Dec;76(3):208-17
pubmed: 20005123
Nutr Cancer. 1992;18(2):97-111
pubmed: 1437657
J Neurooncol. 2018 May;138(1):17-27
pubmed: 29357089
J Colloid Interface Sci. 2011 Feb 1;354(1):202-9
pubmed: 21094493
Biochim Biophys Acta. 2014 Sep;1840(9):2730-43
pubmed: 24946270
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii100-3
pubmed: 23253923
Front Oncol. 2014 Jul 29;4:198
pubmed: 25120955
Lab Invest. 2018 Aug;98(8):989-998
pubmed: 29884911
Cancer. 1992 Sep 15;70(6 Suppl):1727-31
pubmed: 1516027
Drug Dev Ind Pharm. 2018 Jul;44(7):1158-1170
pubmed: 29429370
Pharm Res. 2013 Feb;30(2):412-23
pubmed: 22992831
Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:1420-1426
pubmed: 28415433
Chem Phys Lipids. 2016 Oct 29;:
pubmed: 27983957
Discov Med. 2013 May;15(84):301-8
pubmed: 23725603

Auteurs

Ankita Tiwari (A)

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, 470 003 (M.P.), India.

Shivani Saraf (S)

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, 470 003 (M.P.), India.

Ankit Jain (A)

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, 470 003 (M.P.), India.
Institute of Pharmaceutical Research, GLA University, NH-2, Mathura-Delhi Road, Mathura, 281 406 (U.P.), India.

Pritish K Panda (PK)

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, 470 003 (M.P.), India.

Amit Verma (A)

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, 470 003 (M.P.), India.

Sanjay K Jain (SK)

Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Central University, Sagar, 470 003 (M.P.), India. drskjainin@yahoo.com.
ORCID: 0000-0002-9241-3114

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Techniques d'investigation › Préparation de médicament › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Phénomènes génétiques › Structures génétiques › Séquences d'acides nucléiques régulatrices › Réseaux de régulation génique › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Thérapeutique › Biothérapie › Immunothérapie › Basics to advances in nanotherapy of colorectal cancer.
Recherchemedicale.com › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Basics to advances in nanotherapy of colorectal cancer.